Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Eligo Bioscience is a biotechnology company focused on the development of innovative microbiome therapies. The company leverages cutting-edge technology to engineer beneficial microbes that can specifically target and eliminate harmful bacteria, aiming to treat a range of diseases linked to the human microbiome.

David Bikard

Timothy K. Lu

Xavier Duportet

Luciano Marraffini

Eligo Bioscience

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Abcam plc

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Metric
Company Name	Biotech 365	Eligo Bioscience	Abcam plc	ABIVAX Société Anonyme
Symbol			ABC	ABVX
MSH ID	COM:BIOTECH-365	BIO:ELIGO	COM:ABCAM	COM:ABIVAX
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Financial Services & Finance	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology Business Services	Biotechnology	Biotechnology	Biotechnology
Country	FR	FR	GB	FR
Stage
Employee Count		42	1.68K	61
Website	biotech-365.com	eligo.bio	abcam.com	abivax.com
LinkedIn		eligo-bioscience		abivax
Founders

Metric
Market Cap			834.77M
Enterprise Value
Monthly Web Traffic	68	457.01K
Web Traffic Growth	-0.57	0.11
Valuation
Raised Capital		256.94M

Metric
Revenue			401.89M
Revenue (LTM)
Revenue (NTM)
Gross Profit			286.19M
EBITDA			60.40M
Operating Income			8.16M
Net Income			5.61M
EPS			0.03
Diluted EPS			0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.71
Operating Profit Margin			0.02
EBITDA Margin			0.15
Net Profit Margin			0.01
Return on Equity			0.01
Return on Assets			0.00
Return on Capital Employed			0.01

BIOT

COM:BIOTECH-365

Biotech 365

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			578.45
P/B Ratio			3.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple			-2.84

Metric
Days Sales Outstanding
Days Payables Outstanding			51.86
Days Inventory Outstanding			233.95
Operating Cycle			233.95
Cash Conversion Cycle			182.10
Asset Turnover			0.32

Metric
Operating Cash Flow			80.15M
Free Cash Flow			3.95M
Cash Flow to Debt			0.27
Operating Cash Flow/Sales			0.20
Free Cash Flow Yield

Metric
Cash & Equivalents			121.18M
Accounts Receivable
Inventory			74.16M
Goodwill			464.84M
Debt to Capitalization			0.26
Debt to Assets			0.23
Current Ratio			1.13
Quick Ratio			0.51

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.06
R&D to Revenue			0.09
SG&A to Revenue